Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]R. L. Siegel, K. D. Miller and A. Jemal: Cancer statistics, 2015. CA Cancer J Clin, 65(1), 5-29 (2015)

  • [2]I. J. Fidler: The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer, 3(6), 453-8 (2003)

  • [3]S. Nola, S. Sin, F. Bonin, R. Lidereau and K. Driouch: A methodological approach to unravel organ-specific breast cancer metastasis. J Mammary Gland Biol Neoplasia, 17(2), 135-45 (2012)

  • [4]J. O’Shaughnessy: Extending survival with chemotherapy in metastatic breast cancer. Oncologist, 10 Suppl 3, 20-9 (2005)

  • [5]M. M. Shao, J. Liu, J. S. Vong, Y. Niu, B. Germin, P. Tang, A. W. Chan, P. C. Lui, B. K. Law, P. H. Tan and G. M. Tse: A subset of breast cancer predisposes to brain metastasis. Med Mol Morphol, 44(1), 15-20 (2011)

  • [6]I. Hohensee, K. Lamszus, S. Riethdorf, S. Meyer-Staeckling, M. Glatzel, J. Matschke, I. Witzel, M. Westphal, B. Brandt, V. Muller, K. Pantel and H. Wikman: Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. Am J Pathol, 183(1), 83-95 (2013)

  • [7]J. B. Aragon-Ching and J. A. Zujewski: CNS metastasis: an old problem in a new guise. Clin Cancer Res, 13(6), 1644-7 (2007)

  • [8]A. M. Brufsky, M. Mayer, H. S. Rugo, P. A. Kaufman, E. Tan-Chiu, D. Tripathy, I. C. Tudor, L. I. Wang, M. G. Brammer, M. Shing, M. U. Yood and D. A. Yardley: Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res, 17(14), 4834-43 (2011)

  • [9]A. Klein, C. Olendrowitz, R. Schmutzler, J. Hampl, P. M. Schlag, N. Maass, N. Arnold, R. Wessel, J. Ramser, A. Meindl, S. Scherneck and S. Seitz: Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett, 276(2), 212-20 (2009)

  • [10]N. Niikura, N. Hayashi, N. Masuda, S. Takashima, R. Nakamura, K. Watanabe, C. Kanbayashi, M. Ishida, Y. Hozumi, M. Tsuneizumi, N. Kondo, Y. Naito, Y. Honda, A. Matsui, T. Fujisawa, R. Oshitanai, H. Yasojima, Y. Tokuda, S. Saji and H. Iwata: Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat, 147(1), 103-12 (2014)

  • [11]N. U. Lin: Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience, 7, 307 (2013)

  • [12]D. Greene-Schloesser, V. Payne, A. M. Peiffer, F. C. Hsu, D. R. Riddle, W. Zhao, M. D. Chan, L. Metheny-Barlow and M. E. Robbins: The peroxisomal proliferator-activated receptor (PPAR) alpha agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment. Radiat Res, 181(1), 33-44 (2014)

  • [13]E. D. Moore, M. Kooshki, K. T. Wheeler, L. J. Metheny-Barlow and M. E. Robbins: Differential expression of Homer1a in the hippocampus and cortex likely plays a role in radiation-induced brain injury. Radiat Res, 181(1), 21-32 (2014)

  • [14]C. M. Perou, T. Sorlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lonning, A. L. Borresen-Dale, P. O. Brown and D. Botstein: Molecular portraits of human breast tumours. Nature, 406(6797), 747-52 (2000)

  • [15]T. Sorlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, P. E. Lonning and A. L. Borresen-Dale: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98(19), 10869-74 (2001)

  • [16]M. De Brot, F. A. Soares, M. M. Stiepcich, V. S. Curcio and H. Gobbi: (Basal-like breast cancers: clinicopathological features and outcome). Rev Assoc Med Bras, 55(5), 529-34 (2009)

  • [17]A. A. Abou-Bakr and H. I. Eldweny: p16 expression correlates with basal-like triple-negative breast carcinoma. Ecancermedicalscience, 7, 317 (2013)

  • [18]S. Kuba, M. Ishida, Y. Nakamura, K. Yamanouchi, S. Minami, K. Taguchi, S. Eguchi and S. Ohno: Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype. Jpn J Clin Oncol, 44(11), 1025-31 (2014)

  • [19]W. Han and H. W. Lo: Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett, 318(2), 124-34 (2012)

  • [20]T. Akiyama, C. Sudo, H. Ogawara, K. Toyoshima and T. Yamamoto: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232(4758), 1644-6 (1986)

  • [21]M. H. Kraus, W. Issing, T. Miki, N. C. Popescu and S. A. Aaronson: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proceedings of the National Academy of Sciences, 86(23), 9193-9197 (1989)

  • [22]G. D. Plowman, J. M. Culouscou, G. S. Whitney, J. M. Green, G. W. Carlton, L. Foy, M. G. Neubauer and M. Shoyab: Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A, 90(5), 1746-50 (1993)

  • [23]H. W. Lo: Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discov Med, 10(50), 44-51 (2010)

  • [24]W. Han and H.-W. Lo: Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Letters, 318(2), 124-134 (2012)

  • [25]R. Carpenter and H.-W. Lo: Regulation of Apoptosis by HER2 in Breast Cancer. Journal of Carcinogenesis & Mutagenesis S7, 300 (2013)

  • [26]N. L. Grupka, K. C. Lear-Kaul, B. K. Kleinschmidt-DeMasters and M. Singh: Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status. Arch Pathol Lab Med, 128(9), 974-9 (2004)

  • [27]J. Gaedcke, F. Traub, S. Milde, L. Wilkens, A. Stan, H. Ostertag, M. Christgen, R. von Wasielewski and H. H. Kreipe: Predominance of the basal type and HER-2//neu type in brain metastasis from breast cancer. Mod Pathol, 20(8), 864-870 (2007)

  • [28]H. W. Lo, W. Xia, Y. Wei, M. Ali-Seyed, S. F. Huang and M. C. Hung: Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res, 65(1), 338-48 (2005)

  • [29]V. Roy and E. A. Perez: Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. The Oncologist, 14(11), 1061-1069 (2009)

  • [30]E. Lim and N. U. Lin: Updates on the management of breast cancer brain metastases. Oncology (Williston Park), 28(7), 572-8 (2014)

  • [31]S. Cohen: Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem, 237, 1555-62 (1962)

  • [32]S. Cohen, G. Carpenter and L. King, Jr.: Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem, 255(10), 4834-42 (1980)

  • [33]S. Cohen, G. Carpenter and L. King, Jr.: Epidermal growth factor-receptor-protein kinase interactions. Prog Clin Biol Res, 66 Pt A, 557-67 (1981)

  • [34]S. Cohen, H. Ushiro, C. Stoscheck and M. Chinkers: A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem, 257(3), 1523-31 (1982)

  • [35]D. Anderson, C. A. Koch, L. Grey, C. Ellis, M. F. Moran and T. Pawson: Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. Science, 250(4983), 979-82 (1990)

  • [36]T. Bowman, M. A. Broome, D. Sinibaldi, W. Wharton, W. J. Pledger, J. M. Sedivy, R. Irby, T. Yeatman, S. A. Courtneidge and R. Jove: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proceedings of the National Academy of Sciences, 98(13), 7319-7324 (2001)

  • [37]R. N. Jorissen, F. Walker, N. Pouliot, T. P. Garrett, C. W. Ward and A. W. Burgess: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res, 284(1), 31-53 (2003)

  • [38]O. K. Park, T. S. Schaefer and D. Nathans: in vitro activation of Stat3 by epidermal growth factorreceptorkinase. Proceedings of the National Academy of Sciences, 93(24), 13704-13708 (1996)

  • [39]Y. Yarden and B. Z. Shilo: SnapShot: EGFR signaling pathway. Cell, 131(5), 1018 (2007)

  • [40]R. L. C. Hui-Wen Lo: Regulation of Apoptosis by HER2 in Breast Cancer. Journal of Carcinogenesis & Mutagenesis (2013)

  • [41]E. J. Lowenstein, R. J. Daly, A. G. Batzer, W. Li, B. Margolis, R. Lammers, A. Ullrich, E. Y. Skolnik, D. Bar-Sagi and J. Schlessinger: The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell, 70(3), 431-42 (1992)

  • [42]H. W. Lo: Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets, 10(8), 840-8 (2010)

  • [43]T. Petrocelli and J. M. Slingerland: PTEN deficiency: a role in mammary carcinogenesis. Breast Cancer Res, 3(6), 356-60 (2001)

  • [44]J. Downward: Mechanisms and consequences of activation of protein kinase B/Akt. Current Opinion in Cell Biology, 10(2), 262-267 (1998)

  • [45]B. P. Zhou, Y. Liao, W. Xia, Y. Zou, B. Spohn and M.-C. Hung: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol, 3(11), 973-982 (2001)

  • [46]Z. Zhong, Z. Wen and J. E. Darnell, Jr.: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science, 264(5155), 95-8 (1994)

  • [47]J. E. Darnell: STATs and Gene Regulation. Science, 277(5332), 1630-1635 (1997)

  • [48]J. Turkson and R. Jove: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 19(56), 6613-26 (2000)

  • [49]R. Garcia, T. L. Bowman, G. Niu, H. Yu, S. Minton, C. A. Muro-Cacho, C. E. Cox, R. Falcone, R. Fairclough, S. Parsons, A. Laudano, A. Gazit, A. Levitzki, A. Kraker and R. Jove: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene, 20(20), 2499-513 (2001)

  • [50]R. L. Carpenter and H.-W. Lo: STAT3 Target Genes Relevant to Human Cancers. Cancers, 6(2), 897-925 (2014)

  • [51]H. W. Lo, S. C. Hsu, M. Ali-Seyed, M. Gunduz, W. Xia, Y. Wei, G. Bartholomeusz, J. Y. Shih and M. C. Hung: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell, 7(6), 575-89 (2005)

  • [52]W. Han, R. L. Carpenter, X. Cao and H. W. Lo: STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3. Mol Carcinog, published online: 12 JUN 2012,

  • [53]H. W. Lo, X. Cao, H. Zhu and F. Ali-Osman: Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res, 8(2), 232-45 (2010)

  • [54]S. C. Wang, Y. Nakajima, Y. L. Yu, W. Xia, C. T. Chen, C. C. Yang, E. W. McIntush, L. Y. Li, D. H. Hawke, R. Kobayashi and M. C. Hung: Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol, 8(12), 1359-68 (2006)

  • [55]A. Psyrri, Z. Yu, P. M. Weinberger, C. Sasaki, B. Haffty, R. Camp, D. Rimm and B. A. Burtness: Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res, 11(16), 5856-62 (2005)

  • [56]W. Xia, Y. Wei, Y. Du, J. Liu, B. Chang, Y. L. Yu, L. F. Huo, S. Miller and M. C. Hung: Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog, 48, 610-617 (2009)

  • [57]H. Zhu, X. Cao, F. Ali-Osman, S. Keir and H. W. Lo: EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Lett, 294(1), 101-10 (2010)

  • [58]X. Cao, H. Zhu, F. Ali-Osman and H. W. Lo: EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis. Mol Cancer, 10, 26 (2011)

  • [59]H. W. Lo: EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol, 3(1), 37-52 (2010)

  • [60]H. W. Lo, S. C. Hsu and M. C. Hung: EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat, 95(3), 211-8 (2006)

  • [61]M. F. Rimawi, P. B. Shetty, H. L. Weiss, R. Schiff, C. K. Osborne, G. C. Chamness and R. M. Elledge: EGFR Expression in Breast Cancer Association with biologic phenotype and clinical outcomes. Cancer, 116(5), 1234-1242 (2010)

  • [62]A. L. Schechter, M. C. Hung, L. Vaidyanathan, R. A. Weinberg, T. L. Yang-Feng, U. Francke, A. Ullrich and L. Coussens: The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science, 229(4717), 976-8 (1985)

  • [63]C. I. Bargmann, M. C. Hung and R. A. Weinberg: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature, 319(6050), 226-30 (1986)

  • [64]D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich and W. L. McGuire: Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science, 235(4785), 177-182 (1987)

  • [65]T. Holbro, R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas and N. E. Hynes: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 100(15), 8933-8938 (2003)

  • [66]N. E. Hynes and H. A. Lane: ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews. Cancer, 5(5), 341-354 (2005)

  • [67]C. Wallasch, F. U. Weiss, G. Niederfellner, B. Jallal, W. Issing and A. Ullrich: Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. The EMBO Journal, 14(17), 4267-4275 (1995)

  • [68]D. Harari and Y. Yarden: Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene, 19(53), 6102-6114 (2000)

  • [69]S. R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh and M. E. Greenberg: Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery. Cell, 91(2), 231-241 (1997)

  • [70]A. Siddiqa, L. M. Long, L. Li, R. A. Marciniak and I. Kazhdan: Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer, 8(1) (2008)

  • [71]W. Beguelin, M. C. Diaz Flaque, C. J. Proietti, F. Cayrol, M. A. Rivas, M. Tkach, C. Rosemblit, J. M. Tocci, E. H. Charreau, R. Schillaci and P. V. Elizalde: Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol, 30(23), 5456-72 (2010)

  • [72]R. L. Carpenter, W. Han, I. Paw and H. W. Lo: HER2 phosphorylates and destabilizes pro-apoptotic PUMA, leading to antagonized apoptosis in cancer cells. PLoS One, 8(11), e78836 (2013)

  • [73]A. Wolf-Yadlin, N. Kumar, Y. Zhang, S. Hautaniemi, M. Zaman, H.-D. Kim, V. Grantcharova, D. A. Lauffenburger and F. M. White: Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Molecular Systems Biology, 2, 54-54 (2006)

  • [74]D. J. Slamon, W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich and M. F. Press: Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer. Science, 244(4905), 707-712 (1989)

  • [75]M. A. Lemmon: The EGF receptor family as therapeutic targets in breast cancer. Breast Disease, 18, 33-43 (2003)

  • [76]Y. Yarden and M. X. Sliwkowski: Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2), 127-137 (2001)

  • [77]K. Wu, K. Fukuda, F. Xing, Y. Zhang, S. Sharma, Y. Liu, M. D. Chan, X. Zhou, S. A. Qasem, R. Pochampally, Y. Y. Mo and K. Watabe: Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer. J Biol Chem, 290(15), 9842-54 (2015)

  • [78]F. Xing, A. Kobayashi, H. Okuda, M. Watabe, S. K. Pai, P. R. Pandey, S. Hirota, A. Wilber, Y. Y. Mo, B. E. Moore, W. Liu, K. Fukuda, M. Iiizumi, S. Sharma, Y. Liu, K. Wu, E. Peralta and K. Watabe: Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain. EMBO Mol Med, 5(3), 384-96 (2013)

  • [79]P. D. Bos, X. H. F. Zhang, C. Nadal, W. Shu, R. R. Gomis, D. X. Nguyen, A. J. Minn, M. Van de Vijver, W. Gerald, J. A. Foekens and J. Massagué: Genes that mediate breast cancer metastasis to the brain. Nature, 459(7249), 1005-1009 (2009)

  • [80]Y. Kang, P. M. Siegel, W. Shu, M. Drobnjak, S. M. Kakonen, C. Cordon-Cardo, T. A. Guise and J. Massague: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3(6), 537-49 (2003)

  • [81]S. J. Kim, J. S. Kim, E. S. Park, J. S. Lee, Q. Lin, R. R. Langley, M. Maya, J. He, S. W. Kim, Z. Weihua, K. Balasubramanian, D. Fan, G. B. Mills, M. C. Hung and I. J. Fidler: Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia, 13(3), 286-98 (2011)

  • [82]A. J. Minn, Y. Kang, I. Serganova, G. P. Gupta, D. D. Giri, M. Doubrovin, V. Ponomarev, W. L. Gerald, R. Blasberg and J. Massague: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest, 115(1), 44-55 (2005)

  • [83]L. Ding, M. J. Ellis, S. Li, D. E. Larson, K. Chen, J. W. Wallis, C. C. Harris, M. D. McLellan, R. S. Fulton, L. L. Fulton, R. M. Abbott, J. Hoog, D. J. Dooling, D. C. Koboldt, H. Schmidt, J. Kalicki, Q. Zhang, L. Chen, L. Lin, M. C. Wendl, J. F. McMichael, V. J. Magrini, L. Cook, S. D. McGrath, T. L. Vickery, E. Appelbaum, K. Deschryver, S. Davies, T. Guintoli, L. Lin, R. Crowder, Y. Tao, J. E. Snider, S. M. Smith, A. F. Dukes, G. E. Sanderson, C. S. Pohl, K. D. Delehaunty, C. C. Fronick, K. A. Pape, J. S. Reed, J. S. Robinson, J. S. Hodges, W. Schierding, N. D. Dees, D. Shen, D. P. Locke, M. E. Wiechert, J. M. Eldred, J. B. Peck, B. J. Oberkfell, J. T. Lolofie, F. Du, A. E. Hawkins, M. D. O’Laughlin, K. E. Bernard, M. Cunningham, G. Elliott, M. D. Mason, D. M. Thompson, Jr., J. L. Ivanovich, P. J. Goodfellow, C. M. Perou, G. M. Weinstock, R. Aft, M. Watson, T. J. Ley, R. K. Wilson and E. R. Mardis: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature, 464(7291), 999-1005 (2010)

  • [84]H. Kennecke, R. Yerushalmi, R. Woods, M. C. Cheang, D. Voduc, C. H. Speers, T. O. Nielsen and K. Gelmon: Metastatic behavior of breast cancer subtypes. J Clin Oncol, 28(20), 3271-7 (2010)

  • [85]H. W. Lo and M. C. Hung: Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. British Journal of Cancer, 94(2), 184-188 (2006)

  • [86]D. Palmieri, J. L. Bronder, J. M. Herring, T. Yoneda, R. J. Weil, A. M. Stark, R. Kurek, E. Vega-Valle, L. Feigenbaum, D. Halverson, A. O. Vortmeyer, S. M. Steinberg, K. Aldape and P. S. Steeg: Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain. Cancer Research, 67(9), 4190-4198 (2007)

  • [87]L. Da Silva, P. T. Simpson, C. E. Smart, S. Cocciardi, N. Waddell, A. Lane, B. J. Morrison, A. C. Vargas, S. Healey, J. Beesley, P. Pakkiri, S. Parry, N. Kurniawan, L. Reid, P. Keith, P. Faria, E. Pereira, A. Skalova, M. Bilous, R. L. Balleine, H. Do, A. Dobrovic, S. Fox, M. Franco, B. Reynolds, K. K. Khanna, M. Cummings, G. Chenevix-Trench and S. R. Lakhani: HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Research: BCR, 12(4), R46-R46 (2010)

  • [88]H. Wikman, K. Lamszus, N. Detels, L. Uslar, M. Wrage, C. Benner, I. Hohensee, B. Ylstra, K. Eylmann, M. Zapatka, G. Sauter, D. Kemming, M. Glatzel, V. Müller, M. Westphal and K. PanTel: Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Research: BCR, 14(2), R49-R49 (2012)

  • [89]B. Adamo, A. Deal, E. Burrows, J. Geradts, E. Hamilton, K. Blackwell, C. Livasy, K. Fritchie, A. Prat, J. Harrell, M. Ewend, L. Carey, C. Miller and C. Anders: Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Research, 13(6), R125 (2011)

  • [90]L. Zhang, J. A. Ngo, M. D. Wetzel and D. Marchetti: Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer()(). Neoplasia (New York, N.Y.), 17(1), 101-113 (2015)

  • [91]Y. Nadir and B. Brenner: Heparanase multiple effects in cancer. Thromb Res, 133 Suppl 2, S90-4 (2014)

  • [92]L. Zhang, P. Sullivan, J. Suyama and D. Marchetti: Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Mol Cancer Res, 8(2), 278-90 (2010)

  • [93]L. Zhang, L. D. Ridgway, M. A. Wetzel, J. Ngo, W. Yin, D. Kumar, J. C. Goodman, M. D. Groves and D. Marchetti: The identification and characterization of breast cancer CTCs competent for brain metastasis. Science translational medicine, 5(180), 10.1.126/scitranslmed.3005109 (2013)

  • [94]Y. K. Choi, S. M. Woo, S. G. Cho, H. E. Moon, Y. J. Yun, J. W. Kim, D. Y. Noh, B. H. Jang, Y. C. Shin, J. H. Kim, H. D. Shin, S. H. Paek and S. G. Ko: Brain-metastatic triple-negative breast cancer cells regain growth ability by altering gene expression patterns. Cancer Genomics Proteomics, 10(6), 265-75 (2013)

  • [95]D. Bourboulia and W. G. Stetler-Stevenson: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol, 20(3), 161-8 (2010)

  • [96]O. Mendes, H. T. Kim, G. Lungu and G. Stoica: MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metastasis, 24(5), 341-51 (2007)

  • [97]S. Jaganathan, P. Yue, D. C. Paladino, J. Bogdanovic, Q. Huo and J. Turkson: A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One, 6(5), e19605 (2011)

  • [98]S. Y. Lin, K. Makino, W. Xia, A. Matin, Y. Wen, K. Y. Kwong, L. Bourguignon and M. C. Hung: Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol, 3(9), 802-8 (2001)

  • [99]L. Y. Hung, J. T. Tseng, Y. C. Lee, W. Xia, Y. N. Wang, M. L. Wu, Y. H. Chuang, C. H. Lai and W. C. Chang: Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res, 36(13), 4337-51 (2008)

  • [100]W. C. Huang, Y. J. Chen, L. Y. Li, Y. L. Wei, S. C. Hsu, S. L. Tsai, P. C. Chiu, W. P. Huang, Y. N. Wang, C. H. Chen, W. C. Chang, W. C. Chang, A. J. Chen, C. H. Tsai and M. C. Hung: Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem, 286(23), 20558-68 (2011)

  • [101]H. W. Lo, S. C. Hsu, W. Xia, X. Cao, J. Y. Shih, Y. Wei, J. L. Abbruzzese, G. N. Hortobagyi and M. C. Hung: Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res, 67(19), 9066-76 (2007)

  • [102]T. A. Libermann, H. R. Nusbaum, N. Razon, R. Kris, I. Lax, H. Soreq, N. Whittle, M. D. Waterfield, A. Ullrich and J. Schlessinger: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature, 313(5998), 144-7 (1985)

  • [103]B. R. Voldborg, L. Damstrup, M. Spang-Thomsen and H. S. Poulsen: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol, 8(12), 1197-206 (1997)

  • [104]P. A. Humphrey, A. J. Wong, B. Vogelstein, M. R. Zalutsky, G. N. Fuller, G. E. Archer, H. S. Friedman, M. M. Kwatra, S. H. Bigner and D. D. Bigner: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A, 87(11), 4207-11 (1990)

  • [105]A. J. Wong, J. M. Ruppert, S. H. Bigner, C. H. Grzeschik, P. A. Humphrey, D. S. Bigner and B. Vogelstein: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A, 89(7), 2965-9 (1992)

  • [106]H. W. Lo, X. Cao, H. Zhu and F. Ali-Osman: Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res, 14(19), 6042-54 (2008)

  • [107]J. L. Hubbs, J. A. Boyd, D. Hollis, J. P. Chino, M. Saynak and C. R. Kelsey: Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer, 116(21), 5038-46 (2010)

  • [108]T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman and D. A. Haber: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350(21), 2129-39 (2004)

  • [109]J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson and M. Meyerson: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497-500 (2004)

  • [110]N. Hayashi, N. Niikura, N. Masuda, S. Takashima, R. Nakamura, K. Watanabe, C. Kanbayashi, M. Ishida, Y. Hozumi, M. Tsuneizumi, N. Kondo, Y. Naito, Y. Honda, A. Matsui, T. Fujisawa, R. Oshitanai, H. Yasojima, H. Yamauchi, S. Saji and H. Iwata: Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. Breast Cancer Res Treat, 149(1), 277-84 (2015)

  • [111]R. Duchnowska, J. Sperinde, A. Chenna, W. Huang, J. M. Weidler, J. Winslow, M. Haddad, A. Paquet, Y. Lie, T. Trojanowski, T. Mandat, A. Kowalczyk, B. Czartoryska-Arlukowicz, B. Radecka, B. Jarosz, R. Staszkiewicz, E. Kalinka-Warzocha, M. Chudzik, W. Biernat and J. Jassem: Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol (2015)

  • [112]T. Fehm, V. Muller, B. Aktas, W. Janni, A. Schneeweiss, E. Stickeler, C. Lattrich, C. R. Lohberg, E. Solomayer, B. Rack, S. Riethdorf, C. Klein, C. Schindlbeck, K. Brocker, S. Kasimir-Bauer, D. Wallwiener and K. PanTel: HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat, 124(2), 403-12 (2010)

  • [113]S. Riethdorf, V. Muller, L. Zhang, T. Rau, S. Loibl, M. Komor, M. Roller, J. Huober, T. Fehm, I. Schrader, J. Hilfrich, F. Holms, H. Tesch, H. Eidtmann, M. Untch, G. von Minckwitz and K. PanTel: Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res, 16(9), 2634-45 (2010)

  • [114]S. Zhang, W. C. Huang, L. Zhang, C. Zhang, F. J. Lowery, Z. Ding, H. Guo, H. Wang, S. Huang, A. A. Sahin, K. D. Aldape, P. S. Steeg and D. Yu: SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res, 73(18), 5764-74 (2013)

  • [115]B. Gril, D. Palmieri, J. L. Bronder, J. M. Herring, E. Vega-Valle, L. Feigenbaum, D. J. Liewehr, S. M. Steinberg, M. J. Merino, S. D. Rubin and P. S. Steeg: Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain. JNCI Journal of the National Cancer Institute, 100(15), 1092-1103 (2008)

  • [116]P. Gupta and S. K. Srivastava: HER2 mediated de novo production of TGFbeta leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancer. Mol Oncol, 8(8), 1532-47 (2014)

  • [117]M. Grusch, M. Petz, T. Metzner, D. Öztürk, D. Schneller and W. Mikulits: The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy. Current cancer drug targets, 10(8), 849-857 (2010)

  • [118]A. Chow, C. L. Arteaga and S. E. Wang: When tumor suppressor TGFbeta meets the HER2 (ERBB2) oncogene. J Mammary Gland Biol Neoplasia, 16(2), 81-8 (2011)

  • [119]S. C. Wang and M. C. Hung: Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res, 15(21), 6484-9 (2009)

  • [120]D. K. Giri, M. Ali-Seyed, L. Y. Li, D. F. Lee, P. Ling, G. Bartholomeusz, S. C. Wang and M. C. Hung: Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol, 25(24), 11005-18 (2005)

  • [121]A. E. Lenferink, D. Busse, W. M. Flanagan, F. M. Yakes and C. L. Arteaga: ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res, 61(17), 6583-91 (2001)

  • [122]S. C. Wang, H. C. Lien, W. Xia, I. F. Chen, H. W. Lo, Z. Wang, M. Ali-Seyed, D. F. Lee, G. Bartholomeusz, F. Ou-Yang, D. K. Giri and M. C. Hung: Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell, 6(3), 251-61 (2004)

  • [123]R. Vadlamudi, M. Mandal, L. Adam, G. Steinbach, J. Mendelsohn and R. Kumar: Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene, 18(2), 305-14 (1999)

  • [124]S. Douglass, A. P. Meeson, D. Overbeck-Zubrzycka, J. G. Brain, M. R. Bennett, C. A. Lamb, T. W. Lennard, D. Browell, S. Ali and J. A. Kirby: Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12. J Pathol, 234(1), 74-85 (2014)

  • [125]P. Gupta, C. Adkins, P. Lockman and S. K. Srivastava: Metastasis of Breast Tumor Cells to Brain Is Suppressed by Phenethyl Isothiocyanate in a Novel In vivo Metastasis Model. PLoS ONE, 8(6), e67278 (2013)

  • [126]B. Fu, W. Long, Y. Zhang, A. Zhang, F. Miao, Y. Shen, N. Pan, G. Gan, F. Nie, Y. He, J. Zhang and G. Teng: Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer. Sci Rep, 5, 8029 (2015)

  • [127]R. Mo, N. Rao, J. Tonra, S. Waksal and M. Poyurovsky: Abstract 1827: Inhibition of Src, HER2, and EGFR by the multi-kinase inhibitor KD019 overcomes trastuzumab resistance in breast cancer. Cancer Research, 74(19 Supplement), 1827 (2014)

  • [128]V. F. Borges, S. K. L. Chia, S. D’Aloisio, G. Fernetich, B. Sajan, T. McSpadden, R. Chavira, E. Barrett, K. Guthrie, J. Garrus, T. Baetz and S. Moulder: Abstract A050: ARRY-380, an oral HER2 inhibitor: Final phase 1 results and conclusions. Molecular Cancer Research, 11(10 Supplement), A050 (2013)

  • [129]C. Saura, J. A. Garcia-Saenz, B. Xu, W. Harb, R. Moroose, T. Pluard, J. Cortés, C. Kiger, C. Germa, K. Wang, M. Martin, J. Baselga and S.-B. Kim: Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 32(32), 3626-3633 (2014)

  • [130]J. C. Bendell, J. Rodon, H. A. Burris, M. de Jonge, J. Verweij, D. Birle, D. Demanse, S. S. De Buck, Q. C. Ru, M. Peters, M. Goldbrunner and J. Baselga: Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 30(3), 282-290 (2012)

  • [131]W. Janni, T. Sarosiek, B. Karaszewska, J. Pikiel, E. Staroslawska, P. Potemski, C. Salat, E. Brain, C. Caglevic, K. Briggs, M. Desilvio, L. Marini and C. Papadimitriou: A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat, 143(3), 493-505 (2014)

  • [132]D. M. Peereboom, K. A. Winter, I. A. Kim, J. F. De Los Santos, P. W. Sperduto, J. R. White and M. P. Mehta: RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metastasis from HER2-positive breast cancer--A collaborative study of RTOG and KROG (NCT01622868). ASCO Meeting Abstracts, 32(15_suppl), TPS664 (2014)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Article

EGFR and HER2 signaling in breast cancer brain metastasis

Sherona R. Sirkisoon 1, Richard L. Carpenter 1, Tadas Rimkus 1, Lance Miller 1,3,4, Linda Metheny-Barlow 1,2,3,4, Hui-Wen Lo 1,3,4,*
Affiliations
Article Info

1 Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC27157

2 Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC27157

3 Department of Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC27157

4 Department of Breast Cancer Center of Excellence, Wake Forest University School of Medicine, Winston-Salem, NC27157, Wake Forest University School of Medicine, Winston-Salem, NC27157

*Author to whom correspondence should be addressed.

 

Abstract

Breast cancer occurs in approximately 1 in 8 women and 1 in 37 women with breast cancer succumbed to the disease. Over the past decades, new diagnostic tools and treatments have substantially improved the prognosis of women with local diseases. However, women with metastatic disease still have a dismal prognosis without effective treatments. Among different molecular subtypes of breast cancer, the HER2-enriched and basal-like subtypes typically have higher rates of metastasis to the brain. Basal-like metastatic breast tumors frequently express EGFR. Consequently, HER2- and EGFR-targeted therapies are being used in the clinic and/or evaluated in clinical trials for treating breast cancer patients with brain metastases. In this review, we will first provide an overview of the HER2 and EGFR signaling pathways. The roles that EGFR and HER2 play in breast cancer metastasis to the brain will then be discussed. Finally, we will summarize the preclinical and clinical effects of EGFR- and HER2-targeted therapies on breast cancer metastasis.

Keywords

  • Breast Cancer
  • Brain Metastasis
  • EGFR
  • HER2

References